We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS has awarded an $877.5 million contract to VaxGen to develop, test and manufacture enough new anthrax vaccine to inoculate millions of Americans in the event of a bioterrorist attack using inhalation anthrax.
HHS has awarded Aventis a multimillion-dollar contract to ensure enough chicken eggs are available to sustain year-round, full-capacity manufacturing of pandemic influenza vaccine.
Some pharmaceutical firms in 2002 overcharged public-health facilities participating in a federal drug-discount program by tens of millions of dollars, according to a follow-up study by HHS’ Office of Inspector General (OIG).
Aventis, part of the Sanofi-Aventis Group, has been awarded a multimillion-dollar contract by HHS to ensure enough chicken eggs are available to sustain year-round, full-capacity manufacturing of pandemic influenza vaccine.
VaxGen has been awarded an $877.5 million contract from HHS to develop, test and manufacture enough new anthrax vaccine to inoculate millions of Americans in the event of a bioterrorist attack using inhalation anthrax.
The FDA has identified roughly 5 million additional doses of flu vaccine from foreign suppliers that could help offset the U.S. flu vaccine shortage, according to HHS.
After “numerous” requests, the Centers for Medicare & Medicaid Services (CMS) is soliciting recommendations from the public on how to change the way Medicare selects cancers for positron emission tomography (PET) scan reimbursement.
Determining the extent to which the FDA monitors postmarketing study commitments and evaluating the pharmaceutical industry's compliance with requirements that submit data on clinical trials involving serious conditions are among the investigations HHS' Office of Inspector General (OIG) plans to undertake in fiscal 2005.
The U.S. Pharmacopeia’s (USP’s) model guidelines for Medicare drug plans will allow any eligible Medicare drug to appear on a plan sponsor’s formulary, said the head of USP.